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their early experience with the Endologix AFX (Irvine, Calif) with
the so-called “Activeseal” endovascular device in more than 100patients with infrarenal aortic aneurysmdapproximately 40%
outside the instructions for usedwith excellent midterm results;
no ruptures, no limb occlusions, no stent fractures, and no
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884 Welborn et al October 2014aneurysm-related deaths. In the words of Spence Taylor, “What’s
not to like?”
As an aside, I would remind the audience that Teﬂon is slick. I
used a 20-mm limb extension to cover an aortic pseudoaneurysm in
a young patient after a thoracic gun shot wound a few years ago. I
was dismayed to ﬁnd on a follow-up computed tomography scan
that the covered stent had migrated distally, covering the celiac
trunk. It was just such migration with the ancestral version of this
graft that led to the current strategy to build up from the aortic
bifurcation.
1. Neck dilation. The AFX device joins a family of new endovas-
cular devices that includes most notably the Endologix Nellix
and Trivascular Ovation that share unique design features
that achieve aneurysm exclusion without applying constant
outward force on the aortic neck. Virtually all of the traditional
endovascular aortic aneurysm repair devices have reported vary-
ing degrees of “neck dilation” after long-term follow-up, and
yet, the development of proximal endoleaks is distinctly un-
common if the device is implanted into a normal aortic neck.
My ﬁrst question is, does neck dilation matter and does its
avoidance represent an important design goal in future devices?
2. There were two type Ia, one type Ib, and one type III endoleak
in the 75% who were followed with computed tomography
scan. As you have pointed out, the strata polytetraﬂuoroethy-
lene material is located exterior to the metal scaffolding which
allows the material to billow out. An imaging cohort showed
extension of the anatomic neck related to this billowing. Inter-
estingly, there were very few type II endoleaks which have been
attributed to the ability of the fabric to cover the entire length of
the infrarenal aorta. Are you aware of any data using either pres-
sure wires or CardioMems pressure sensors regarding whether
the design of the AFX device allows the excessive or ongoing
transmission of pressure to the aneurysm wall? And, is there
any consequence?
3. I notice that you have used an ipsilateral cut down despite the
fact that the device has a percutaneous endovascular anerusym
repair (PEVAR) indication. Do you expect to adopt this prac-
tice in future, and if not, why not?
4. Finally, where do you ﬁt this device into your current armamen-
tarium? In what patients do you preferentially use this device?
Thank you for presenting your data.
Dr M. Burress Welborn III. Thank you very much for the
questions.The ﬁrst question regards neck dilatation. We oversize the
aortic neck for the AFX graft more than other products. In patients
with challenging necks we are more aggressive with oversizing.
Often we end up oversizing >20%. The proximal stent has very lit-
tle radial force. There is no indication from the original Powerlink
device (Endologix) investigational device exemption studies that
there was any neck dilatation. The AFX device is the second-gen-
eration of the Powerlink device so I expect no difference. I do not
think that AFX stent component has much effect on neck dilata-
tion. Clearly we will have to see what happens. The next issue is
whether or not that constant pressure from unattached graft will
result in neck dilation. We certainly have not seen this but this
needs to be considered. I think it is still too early to make any con-
clusions because our data represent only midterm results. Only
longer-term data will tell us if either mechanism results in aortic
neck dilation.
The second question concerns intrasac pressure. There are
some unpublished data from Cardiomems on intrasac pressure
with the Powerlink device. The intrasac pressure when you initially
put the graft in is quite high, but then after 45 to 60 days the intra-
sac pressure decreases to pressures that have been published for
other devices. There are no data that I am aware of that suggests
elevated intrasac pressures after placement of the AFX device.
The third question concerned PEVAR. I have been hesitant to
get into PEVAR. My partner does PEVAR. I do not perform
PEVAR because of personal reasons. I perform surgery on Friday
and the last thing I want to do is get a call about an access site
complication when I am spending time with my loved ones.
The ﬁnal question is, in which patients to I chose to place an
AFX device. The question is when do I use this device? My ques-
tion is when don’t I use the device? The AFX device is great for
saccular aneurysms. I think it is the ideal graft for saccular aneu-
rysms. The AFX device is great for normal aortic bifurcations
and the device is ideal for patients who have infrainguinal disease
that you are going to have to go back and intervene later. I think
the one pitfall is patients who have very large iliac artery aneurysms
in whom you do not have an aortic bifurcation on which you can
reliably seat the graft. The real strength of the graft is that its ﬁx-
ation is at the aortic bifurcation. The issues of the neck sealing
zone and neck coverage are important but the device uses the
aortic bifurcation as the primary site of ﬁxation. Patients with large
iliac aneurysm and compromised aortic bifurcations are, in my
opinion, not ideal candidates for the AFX device.
